Evidence map›Paper›PMID 42609527›Full record

ArticleFrontiers in microbiology2026

Integrated computational and experimental evaluation of natural products targeting PGM/AlgC and HisIE in multidrug-resistant respiratory pathogens.

Zhe Wang, Wei Lu, Bing Li, Tianxu Wang, Qiushi Liu, Yunxiang Lv, Kexing Han, Xin Li

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhe Wang *Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Jinzhou Medical, Jinzhou, Liaoning, China.
Wei Lu *Department of Respiratory and Critical Care Medicine, General Hospital of Northern Theater Command of the Chinese People's Liberation Army, Shenyang, Liaoning, China.
Bing LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Jinzhou Medical, Jinzhou, Liaoning, China.
Tianxu WangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Jinzhou Medical, Jinzhou, Liaoning, China.
Qiushi LiuDepartment of Respiratory and Critical Care Medicine, General Hospital of Northern Theater Command of the Chinese People's Liberation Army, Shenyang, Liaoning, China.
Yunxiang LvDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Kexing HanDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Xin LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Jinzhou Medical, Jinzhou, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The increasing prevalence of multidrug-resistant (MDR) Gram-negative respiratory pathogens has reduced the effectiveness of conventional antimicrobial therapies and created a need for antibacterial strategies targeting bacterial metabolic and virulence-associated functions. AlgC, a phosphomannomutase/phosphoglucomutase involved in cell-envelope and exopolysaccharide biosynthesis, and the bifunctional histidine-biosynthesis enzyme HisIE represent potentially relevant bacterial targets. Objective: This study evaluated the antibacterial and enzyme-inhibitory activities of three natural products, 5-hydroxysophoranone, 10'-desmethoxystreptonigrin, and isoforsythiaside-and investigated their predicted interactions with AlgC and HisIE using an integrated computational and Methods: Molecular docking was performed to examine the interactions of the selected compounds with the predicted catalytic or ligand-binding regions of AlgC and HisIE. Two lead protein-ligand complexes were subsequently evaluated using 500-ns molecular dynamics simulations and MM/GBSA analysis. Antibacterial activity against MDR respiratory isolates was assessed using broth dilution and disc-diffusion assays. Cytotoxicity was examined in A549 and BEAS-2B epithelial cells using the MTT assay. Cell-associated antibacterial activity, recombinant-enzyme inhibition, Western blotting, and quantitative real-time PCR were used to assess antibacterial effects and changes in selected metabolic and virulence-associated markers. Results: The selected natural products showed favorable predicted interactions with the investigated AlgC and HisIE binding regions. Among the tested compounds, 10'-desmethoxystreptonigrin exhibited the strongest predicted interaction with AlgC and showed the lowest minimum inhibitory concentrations, the greatest reduction in cell-associated bacterial burden, and the strongest inhibition of the recombinant enzymes. The two simulated lead complexes retained generally stable protein-ligand interactions during the molecular dynamics trajectories. Treatment with the compounds was also associated with reduced expression of selected metabolic and virulence-associated markers, including pgm/algC, hisIE, lasR, pslA, and ompA. Isoforsythiaside demonstrated comparatively greater epithelial-cell compatibility, whereas 10'-desmethoxystreptonigrin showed greater antibacterial potency but lower host-cell tolerance. Conclusion: The combined computational and experimental findings identify 10'-desmethoxystreptonigrin and 5-hydroxysophoranone as candidate natural-product scaffolds with antibacterial and recombinant AlgC/HisIE-inhibitory activities. The observed enzyme inhibition and changes in selected molecular markers are consistent with possible interference in AlgC- and HisIE-associated processes; however, they do not by themselves establish direct intracellular target engagement or pathway-specific causality. Further studies using target-engagement assays, genetically defined bacterial strains, broader clinical-isolate panels, biofilm and quorum-sensing assays, and

Indexed as

Acinetobacter baumanniiantimicrobial resistanceHisIElower respiratory tract infectionsmolecular dockingmolecular dynamics simulationmultidrug-resistant bacterianatural compounds

Identifiers

PMID42609527
PMCPMC13478258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.